Bayesian optimization for estimating the maximum tolerated dose in Phase I clinical trials
Open Access
- 1 March 2021
- journal article
- research article
- Published by Elsevier in Contemporary Clinical Trials Communications
- Vol. 21, 100753
Abstract
No abstract availableKeywords
Funding Information
- Japan Society for the Promotion of Science
- Tokyo Institute of Technology
This publication has 38 references indexed in Scilit:
- Principles of dose finding studies in cancer: a comparison of trial designsCancer Chemotherapy and Pharmacology, 2013
- Calibration of prior variance in the Bayesian continual reassessment methodStatistics in Medicine, 2011
- A simulation-based comparison of the traditional method, Rolling-6 design and a frequentist version of the continual reassessment method with special attention to trial duration in pediatric Phase I oncology trialsContemporary Clinical Trials, 2010
- A comparison of model choices for the continual reassessment method in phase I cancer trialsStatistics in Medicine, 2009
- Model calibration in the continual reassessment methodClinical Trials, 2009
- Dose Escalation Methods in Phase I Cancer Clinical TrialsJNCI: Journal of the National Cancer Institute, 2009
- Continual Reassessment Method vs. Traditional Empirically Based Design: Modifications Motivated by Phase I Trials in Pediatric Oncology by the Pediatric Brain Tumor ConsortiumJournal of Biopharmaceutical Statistics, 2009
- A comprehensive comparison of the continual reassessment method to the standard 3 + 3 dose escalation scheme in Phase I dose-finding studiesClinical Trials, 2008
- Some practical improvements in the continual reassessment method for phase I studiesStatistics in Medicine, 1995
- Statistical and Ethical Issues in the Design and Conduct of Phase I and II Clinical Trials of New Anticancer AgentsJNCI: Journal of the National Cancer Institute, 1993